FDA examines peptide injection approvals

Health advisers are reviewing the safety and efficacy of more than six peptides, unproven substances popular in wellness circles but lacking sufficient clinical evidence. The two-day FDA meeting, supported by Health Secretary Kennedy and attended by industry-linked experts, aims to decide whether to add these peptides to a list allowing pharmacies to compound them safely. Regulators remain skeptical due to limited human data and concerns about safety risks, though some industry supporters advocate for easier access amid public claims of benefits. A final decision is expected after considering votes, public comment, and ongoing discussions.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل